62 completed, 23 active not recruiting, 18 recruiting, 18 terminated. 143 Phase 2, 21 Phase 1, 3 Phase 3.
Follow Abiraterone Acetate: new trials by email Literature Review of Abiraterone Acetate trials Research Report on Abiraterone Acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer QLC5508, abiraterone acetate, enzalutamide - Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 212 | 2025-11-05 | 2026-06-02 |
| Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Abiraterone Acetate - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation | Phase 2 | Withdrawn | Qian Qin | 2025-10-01 | 2026-04-08 | |
| Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer QLH12016, abiraterone acetate, enzalutamide - Prostatic Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 50 | 2025-10-01 | 2025-08-05 |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer ASP5541, Prednisone, Prednisolone - Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 218 | 2025-08-19 | 2026-09-03 |
| Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer Abiraterone acetate, Dexamethasone, Metronidazole - Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 58 | 2025-02-13 | 2026-02-19 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-11-03 |
| Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C) - High Risk Prostate Carcinoma, Prostate Cancer | Phase 2 | Active not recruiting | Ivan de Kouchkovsky, MD | 32 | 2024-12-09 | 2026-09-04 |
| Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone. - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Jianbin Bi | 40 | 2024-11-27 | 2025-05-14 |
| Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer. Dalpicilib, Abiraterone Acetate (II), Androgen Deprivation Therapy - The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer | Phase 2 | Not yet recruiting | Qilu Hospital of Shandong University | 43 | 2024-07-31 | 2024-07-15 |
| A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer Tinengotinib, abiraterone acetate with prednisone, Enzalutamide - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2024-06-04 | 2026-06-25 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss Capivasertib, abiraterone acetate - High-Risk Prostate Cancer | Phase 2 | Recruiting | VA Office of Research and Development | 30 | 2024-05-31 | 2026-10-26 |
| Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients. Xtandi, Zytiga® (Abiraterone Acetate), SBRT - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Recruiting | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | 51 | 2024-05-16 | 2026-07-21 |
| Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 110 | 2024-04-22 | 2026-09-25 |
| High-Risk Metachronous Oligometastatic Prostate Cancer Trial niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT) - Prostate Cancer, Oligometastatic Disease | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 88 | 2024-04-17 | 2026-05-06 |
| CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2024-03-05 | 2026-07-22 |
| A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer Neoadjuvant treatment - Prostate Cancer | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2024-01-01 | 2024-03-18 |
Showing 20 of 143. Sign in to see all of them.
Prostatic Neoplasms (108) · Neoplasm Metastasis (7) · Prostatic Neoplasms, Castration-Resistant (6) · Breast Neoplasms (5) · Neoplasms (3) · Adenocarcinoma (2) · Genital Neoplasms, Male (2) · Urogenital Neoplasms (2) · Adrenal Hyperplasia, Congenital (1) · Adrenocortical Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Cushing Syndrome (1) · Genital Diseases, Male (1) · Hyperaldosteronism (1)
M.D. Anderson Cancer Center (10) · Janssen Research & Development, LLC (7) · University of Washington (6) · Cougar Biotechnology, Inc. (4) · Dana-Farber Cancer Institute (4) · Mayo Clinic (4) · Memorial Sloan Kettering Cancer Center (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Astellas Pharma Global Development, Inc. (3) · British Columbia Cancer Agency (3) · Sun Pharmaceutical Industries Limited (3) · West China Hospital (3) · Duke University (2) · ECOG-ACRIN Cancer Research Group (2) · Fudan University (2)
United States (98) · United Kingdom (17) · China (16) · Canada (11) · Spain (9) · France (8) · Italy (6) · Australia (5) · Belgium (5) · Germany (5) · Netherlands (5) · South Korea (5) · Brazil (3) · Japan (3) · Poland (3)
Cougar Biotechnology, Inc. Clinical Trial (3) · Mary-Ellen Taplin, MD (3) · Michael Schweizer (3) · Christopher Logothetis (2) · Christopher Logothetis, MD (2) · Daniel George, MD (2) · Kim N Chi, MD (2) · Robert Montgomery (2) · Tanya Dorff (2) · Amar Kishan (1)
PMID 21802835, PMID 22747660, PMID 32923850, PMID 39074346, PMID 42186347, PMID 11745214, PMID 14985252, PMID 16172198, PMID 16580903, PMID 16670169, PMID 18619560, PMID 18990168, PMID 19223900, PMID 19500762, PMID 21220434, PMID 21612468, PMID 22452894, PMID 22997446, PMID 23470964, PMID 24210085, PMID 24268504, PMID 24787968, PMID 25091040, PMID 25320358, PMID 26343110, PMID 26353009, PMID 26504153, PMID 26718929, PMID 26719232, PMID 27052658, PMID 27683182, PMID 27742908, PMID 28039155, PMID 28178640, PMID 28300506, PMID 28314838, PMID 28578639, PMID 28655452, PMID 28978327, PMID 29248236, PMID 29261439, PMID 29529169, PMID 29590007, PMID 30355464, PMID 30591354, PMID 30811282, PMID 30935383, PMID 31246234, PMID 31560068, PMID 31727538
2023 (5), 2016 (4), 2017 (3), P30CA015704 (3), P50CA097186 (2), U10CA180820 (2), 2004 (1), 2019 (1), I01CX002517 (1), N01CM00038 (1), N01CM00039 (1), N01CM00071 (1), P30CA014599 (1), P30CA033572 (1), P30CA072720 (1)